The discovery may lead to development of drugs that halt disease progression and stop memory loss
News
Novartis receives vital licence for Scemblix
Therapy represents the first STAMP inhibitor for patients with chronic myeloid leukaemia
NICE recommends Eli Lilly’s breast cancer therapy
Verzenios in combination with endocrine treats people with early breast cancer who are at high-risk of recurrence
Genedrive genetic variant test for infants evaluated by NICE
The MT-RNR1 test was assessed under NICE’s diagnostics assessment programme
Nordic Bioscience and Roche strengthen collaboration
The companies will focus on the development of biomarkers for chronic diseases
Keensight Capital invests in AstraZeneca spin-out
The deal will boost CatSci’s ability to deliver best-in-class medicines to patients worldwide
Jazz and Redx in milestone inhibitor agreement
Jazz Pharmaceuticals and Redx announce that pan-RAF inhibitor will enter clinical development
Merck and Mulliken Center collaborate for machine learning project
The three-year project will focus on molecular representations and computational tools
Spirea raises £2.4m to develop antibody drug conjugates in cancer
Funding will enable the development of Spirea’s pipeline of antibody drug conjugate therapeutics for the treatment of solid tumours
Amarin’s Vazkepa secures NICE recommendation
It is the first treatment in its class to receive NICE approval for cardiovascular risk reduction
First patient dosed in Scancell’s clinical trial for multiple cancers
First-in-human clinical trial in patients with triple negative breast cancer, ovarian cancer, head and neck cancer and renal cancer
Verona Pharma’s ensifentrine heads for phase 3 chronic obstructive pulmonary disease trial
The company completes its enrolment in phase 3 trial evaluating ensifentrine for treatment of COPD
Ziphius Vaccines and University of Antwerp begin collaboration
The partnership will involve the optimised delivery of saRNA-based vaccines and therapeutics
Coave Therapeutics and ABL link up to develop gene therapy manufacturing processes
Agreement between the two companies includes process development of AAV-based gene therapies
Takeda’s dengue vaccine candidate delivers continued protection
Vital dengue vaccine offers over four years’ protection following successful clinical trial
